Charanraj Goud Alladi

7PUBLICATIONS
22CO-AUTHORS
Gene and molecular therapyMolecular targetsNutrigenomics and personalised nutritionRegenerative medicine (incl. stem cells)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 22, 2026
Repurposed catechol-O-methyltransferase inhibitors tolcapone and entacapone preferentially suppress aggregation and seeding of P301 mutant tau in human neuronal models.

|Oct 16, 2026
Protein Tyrosine Phosphatases in Cancer: From Oncogenic Drivers to Therapeutic Targets.

|Jul 28, 2026
Nutraceuticals for the Management of Cardiovascular Health: A Mechanistic and Evidence-Based Review Focusing on Atherosclerosis and Hypertension.

|Mar 15, 2023
Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems.

Ana Lokmer, Charanraj Goud Alladi, Réjane Troudet

|Feb 14, 2023
Impact of pharmacogenomics in achieving personalized/precision medicine in the clinical setting: a symposium report.

Reka Devanathan, Charanraj Goud Alladi, Mirunalini Ravichandran

|Oct 18, 2018
Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.

Charanraj Goud Alladi, Ravi Philip RajKumar, Surendiran Adithan

Pageof 2

Frequent Collaborators

2 joint publications

Cynthia Marie-Claire

1 joint publications

Ihor Kozlov

1 joint publications

Yu-Sheng Hung

1 joint publications

Sudeep Roy